RECENTLY ADDED

  • Treatment of Opioid Use Disorder: Waiver Qualifying - ACOG - Champaign, IL - Monday, December 3, 2018

    Contains 24 Component(s), Medical Credits Offered

    The ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements will ensure that participants are exposed to the highest quality, evidence-based practices when using buprenorphine to treat opioid use disorders.

    image



    image


    Monday, December 3, 2018 | 10:00 am - 2:30 pm

    Carle at the Fields, Excellence Room
    3310 Fields S. Dr. 
    Champaign, IL 61822

    Cost: $100

    This course is offered in partnership with the American College of Obstetricians and Gynecologists. The curriculum for this course has been specifically designed for women's health providers.

    Welcome to the ASAM Treatment of Opioid Use Disorder Course online access. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training.

    This is an 8-hour blended course combining 4 hours of online learning followed by 4 hours of live learning. The live portion of the course builds off the content delivered in the online portion. Course faculty are expecting you to come to the live course with the online portion completed. 

    Getting started: To begin the online portion of the course, please log in to your right and locate the box that says Module 1. If you do not know your password, or you have forgotten it, select Forgot Password and you will be emailed a link to reset your password. Detailed instructions for completing the online portion of the course can be found under the tab titled Course Instructions.

    Once you have completed the 4-hour online portion and the 4-hour live portion of the course, return here to claim CME for the course. If you have any questions, please contact education@ASAM.org.


    Overview of Legislation

    Physicians

    The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

    Nurse Practitioners & Physician Assistants

    On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

    To qualify, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
    • Complete not less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD  
    • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

    HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.

    NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:

    Apply

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs and PAs from prescribing these medications even if Federal law allows it.

    Apply

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

    Qualify 

    To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain
    • Complete no less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD
    • If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

     

    CME Information and Disclosure Listing

    Date of Release: July 2015
    Approved Through: July 2018

    The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The American Society of Addiction Medicine designates this enduring material for a maximum of 4 AMA PRA Category 1 Credits. Physicians should claim only credit commensurate with the extent of their participation in the activity.

    The American Society of Addiction Medicine designates this live activity for a maximum of 4 AMA PRA Category 1 Credits. Physicians should claim only credit commensurate with the extent of their participation in the activity.

    The combined online enduring material and live activity will provide the required 8 hours needed to obtain the waiver to prescribe buprenorphine in office-based treatment of opioid use disorders.

    This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 8 AMA PRA Category 1 Credit(s)™ to the CME requirement for Part II: Lifelong Learning and Self-Assessment.

    In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    ASAM CME Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Catherine R. Friedman, MD, FASAM Chair

    None

    Edwin A. Salsitz, MD, FASAM

    None

    Herbert Malinoff, MD, FACP, FASAM

    None



    Noel Ilogu, MD, MRCP

    None

    Abigail Kay, MD

    None

    John Tanner, DO, FASAM

    Reckitt Benckiser

    OREXO

    BDSI

    Honorarium

    Honorarium

    Honorarium

    Speaker

    Speaker

    Speaker and Consultant

    Catherine Friedman, MD

    None

    ASAM Buprenorphine Program Planning Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Dan Alford, MD, MPH

    None

    Andrew J. Saxon, MD

    UpToDate

    Royalties

    Section Editor, Drug Use Disorders

    Colleen LaBelle, BSN, RN-BC, CARN

    None

    Edwin Salsitz, MD, FASAM

    None

    Jeffrey D. Baxter, MD

    None

    Kelley Saia, MD

    None

    Sharon Levy, MD, MPH

    None

    Paula J. Lum, MD, MPH

    None


    ASAM Buprenorphine Course Faculty

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Edwin Salsitz, MD, FASAM

    None

    Andrew J. Saxon, MD

    UpToDate

    Royalties

    Senior Editor, Drug Use Disorders

    Colleen LaBelle, BSN, RN-BC, CARN

    None

    Dan A. Alford, MD, MPH

    None

    Jeffrey D. Baxter, MD

    None

    Kelley Saia, MD

    None

    Sharon Levy, MD, MPH

    None

    Paula J. Lum, MD, MPH

    None

    Sarah Bagley, MD

    ASAM Millennium Fellowship Award

    Partial Salary Support

    Awardee

    Alexander Y. Walley, MD, MSc

    None

    ASAM CME Committee Reviewers

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Adam J. Gordon, MD, MPH, FACP, FASAM

    None

    Herbert Malinoff, MD, FACP, FASAM

    None

    Learners will be able to:

    1. Apply for a waiver to prescribe buprenorphine to their patients with opioid use disorders
    2. Identify and assess patients who are appropriate for treatment with medications
    3. Have specific knowledge concerning the use of medications to manage patients with addiction involving opioid use
    4. Discuss the psychiatric and medical co-morbidities associated with opioid addiction
    1. Locate the box on the right that says “Module 1" and click “View Web Content On-Demand"
    2. Locate the box on the right that says “Certificate code" and enter the code given upon completion of Module 1 Part 1
    3. Continue to Module 1 Part 2 and Module 1 Part 3
    4. Once you have completed the entire module, locate the box called “Module 1 Quiz" and choose “Take Quiz"
    5. After you have completed Module 1 Quiz, continue to modules 2 and 3
    6. You will be required to pass all 3 Module Quizzes with a grade of 70% or higher
    7. Upon completion of both the 4 online hours and 4 live hours of the course, you will be able to claim CME Credit through the ASAM e-Learning Center
    1. Physicians, Nurse Practitioners, and Physician Assistants who wish to obtain a waiver to prescribe buprenorphine in office based treatment of opioid use disorders.
    2. Clinicians and health care team members working with physicians who prescribe buprenorphine in office based treatment of opioid use disorders.

    The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior Inc.

  • Session 1: The Opioid Crisis: Current Status and Treatment Responses (2.25 CME)

    Contains 3 Component(s), Medical Credits Offered

    Earn 2.25 AMA PRA Category 1 Credit(s)™ while learning more about the current status and treatment responses to address the opioid crisis, from this conference recording from The ASAM State of the Art Conference, 2018.

    Session 1 examines several topics in the field of opioid-related morbidity and mortality, as well as the treatment of opioid use disorder. Presenters will dive into updates on opioid misuse, overdose epidemiology, and current national trends. This will be followed by an updated review of evidence-based strategies for opioid overdose prevention, and an overview of data that are the basis of current approaches for the investigation of novel kappa-opioid receptor ligands for the treatment of opioid use disorder. Finally, we will close with a review of recent clinical trials examining the efficacy and effectiveness of extended-release (XR) medications for the treatment of opioid use disorder. Richard C. Dart, MD, PhD, Alexander Y. Walley, MD, MSc, FSAM, Eduardo R. Butelman, PhD, and Joshua D. Lee, MD, MSc bring their years of experience and expertise to deliver an exceptional presentation covering the following: Opioid Epidemiology in the Age of Fentanyl, Opioid Overdose Prevention and Management in a Dynamic Opioid Crisis, Targeting the Kappa-Opioid Receptor System for Developing New Pharmacotherapies for Opioid Use Disorder, and Long-Acting Naltrexone and Buprenorphine Formulations: Efficacy Effectiveness and Comparative Effectiveness.

  • Session 2: Cocaine: How the Cellular Basis of its Impact Tells the Story (2 CME)

    Contains 3 Component(s), Medical Credits Offered

    Earn 2 AMA PRA Category 1 Credit(s)™ while learning more about cocaine and how the cellular basis of its impact tells the story, from this conference recording from The ASAM State of the Art Conference, 2018.

    In session 2, you will learn that cocaine is not just for the 80’s stock broker anymore! The subcellular pharmacokinetics make this a particularly difficult substance to treat. We will walk through the advanced neuroscience, the animal models that define our predictive understanding, and the behavioral aspects of both the pathology and treatment. While opioids have captured recent headlines, cocaine and its close cousin methamphetamine have been smoldering in the background. Although we do not have medications with good evidence for treatment, we can predict the withdrawal syndrome and the behaviors that drive utilization. With this knowledge we can build better interventions that are both helpful and reimbursed. 
  • Session 3: Implications of Expanded Cannabis Access (2 CME)

    Contains 3 Component(s), Medical Credits Offered

    Earn 2 AMA PRA Category 1 Credit(s)™ while learning more about the implications of expanded access to cannabis, from this conference recording from The ASAM State of the Art Conference, 2018.

    Session 3 examines several topics in the field of cannabinoids and cannabis access. This will involve presentations on the epidemiology of cannabis use and cannabis use disorder, followed by an update on cannabis decriminalization, legalization, and use of “medical marijuana” and current laws. Then we will dive into routes of administration, detailed information on “synthetic marijuana,” and the use and consequences thereof. The presentations will describe the consequences of expanded marijuana access in terms of adolescent use, traffic accidents, and marijuana testing in the workplace in states with and without legalization as emerging issues.

    Deborah S. Hasin, PhD, D. Faye Caldwell, JD, Ryan G. Vandrey, PhD, and Michael H. Baumann, PhDbring their years of experience and expertise to deliver an exceptional presentation covering the following:  Epidemiology of Cannabis Use and Cannabis Use Disorder, Reefer Madness? Update on Cannabis Laws and "Medical Marijuana", Routes of Marijuana Administration and Testing, and Biological Effects of Synthetic Cannabinoid Drugs Found in the Street Drug Marketplace.

  • Session 4: Cannabis and Coexisting Disorders (1.5 CME)

    Contains 3 Component(s), Medical Credits Offered

    Earn 1.5 AMA PRA Category 1 Credit(s)™ while learning more about cannabis and coexisting disorders, from this conference recording from The ASAM State of the Art Conference, 2018.

    Session 4 examines several topics in the field of cannabinoids, cannaboid use, and coexisting disorders. As a continuation of cannabis topics, this session will continue with a presentation on advances in pharmacotherapies for cannabis use disorders, the impact and effect of marijuana use on treating other substance use disorders, consequences of expanded marijuana use on opioid usage, and the CBD products. Kevin M. Gray, MD, Dustin C. Lee, PhD, and Rosalie L. Pacula, PhDbring their years of experience and expertise to deliver an exceptional presentation covering the following: Advances with Pharmacotherapies for Cannabis Use Disorder, Impact of Marijuana Use on Treating Other Substance Use Disorders, and The Public Health Impacts of Expanded Cannabis Access.